DE3888378D1 - Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen. - Google Patents

Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.

Info

Publication number
DE3888378D1
DE3888378D1 DE88302808T DE3888378T DE3888378D1 DE 3888378 D1 DE3888378 D1 DE 3888378D1 DE 88302808 T DE88302808 T DE 88302808T DE 3888378 T DE3888378 T DE 3888378T DE 3888378 D1 DE3888378 D1 DE 3888378D1
Authority
DE
Germany
Prior art keywords
androst
monosubstituted
aza
carbamoyl
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE88302808T
Other languages
English (en)
Other versions
DE3888378T2 (de
Inventor
Gary H Rasmusson
Glen F Reynolds
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE3888378D1 publication Critical patent/DE3888378D1/de
Application granted granted Critical
Publication of DE3888378T2 publication Critical patent/DE3888378T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
DE19883888378 1987-04-03 1988-03-30 Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen. Expired - Lifetime DE3888378T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3480887A 1987-04-03 1987-04-03

Publications (2)

Publication Number Publication Date
DE3888378D1 true DE3888378D1 (de) 1994-04-21
DE3888378T2 DE3888378T2 (de) 1994-09-29

Family

ID=21878742

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19883888378 Expired - Lifetime DE3888378T2 (de) 1987-04-03 1988-03-30 Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.

Country Status (5)

Country Link
EP (1) EP0285383B1 (de)
CA (1) CA1302276C (de)
CY (1) CY1808A (de)
DE (1) DE3888378T2 (de)
HK (1) HK116594A (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3838716A1 (de) * 1988-11-15 1990-05-17 Kanoldt Arzneimittel Gmbh Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie
US5364847A (en) * 1989-03-10 1994-11-15 Endorecherche Inhibitors of sex steroid biosynthesis and methods for their production and use
US5595985A (en) 1989-03-10 1997-01-21 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
ATE170753T1 (de) * 1989-07-07 1998-09-15 Endorecherche Inc Androgenderivate zur hemming der aktivität der sexualsteroide
HUT60139A (en) * 1989-07-07 1992-08-28 Endorecherche Inc Process for producing pharmaceutical composition suitable for treating prostate cancer connected with androgen
DE69033020T2 (de) * 1989-07-07 1999-08-05 Endorecherche Inc Kombinationstherapie zur prophylaxe und/oder behandlung benigner prostatahyperplasie
US5300294A (en) * 1990-06-27 1994-04-05 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
US5304562A (en) * 1991-10-09 1994-04-19 Ciba-Geigy Corporation 17β-substituted Aza-androstane derivatives
CA2084799C (en) * 1991-12-17 2003-01-28 Glenn J. Gormley Method of prevention of prostatic carcinoma with 17 beta-n-monosubstituted-carbamoyl-4-aza-5 alpha-androst-1 -en-3-ones
ATE165368T1 (de) * 1991-12-20 1998-05-15 Glaxo Wellcome Inc Inhibitoren von testosteron-5-alpha reductase.
US5994362A (en) * 1992-03-11 1999-11-30 Merck & Co., Inc. Method of treatment for prostatic cancer
KR950701527A (ko) * 1992-05-21 1995-04-28 라브리 페르낭 테스토스테론 5α 환원효소 활성 저해제(INHIBITORS OF TESTOSTERONE 5α-REDUCTASE ACTIVITY)
US5302589A (en) * 1992-08-07 1994-04-12 Glaxo, Inc. Heterocyclic inhibitors of 5-α-testosterone reductase
HU212459B (en) * 1992-10-02 1996-06-28 Richter Gedeon Vegyeszet Process for producing new 17-beta-substituted 4-aza-androstane-derivatives and pharmaceutical compositions containing them
US5468860A (en) * 1992-11-19 1995-11-21 Merck & Co., Inc. New finasteride processes
ES2158887T3 (es) * 1992-12-18 2001-09-16 Merck & Co Inc Procedimiento para tratar la prostatitis cronica con 17 beta-n-terc-butilcarbamoil-4-aza-5 alfa-androst-1-en-ona.
AU6427194A (en) * 1993-04-02 1994-10-24 Ciba-Geigy Ag Aza-androstane-17beta -carboxamides
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
US5547957A (en) 1993-10-15 1996-08-20 Merck & Co., Inc. Method of treating androgenic alopecia with 5-α reductase inhibitors
SK281645B6 (sk) 1993-10-21 2001-06-11 Merck & Co., Inc. 16-substituované-4-azaandrostanové deriváty, farmaceutické prostriedky s ich obsahom a ich použitie
US5637310A (en) * 1993-12-20 1997-06-10 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
US5817818A (en) * 1994-09-16 1998-10-06 Glaxo Wellcome Inc. Androstenones
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US5656613A (en) * 1995-01-04 1997-08-12 Merck & Co., Inc. Treatment of hyperandrogenic conditions
US6177404B1 (en) 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
US6093722A (en) * 1997-02-26 2000-07-25 Sankyo Company, Limited Method for treating prostate cancer
US5998427A (en) * 1998-05-14 1999-12-07 Glaxo Wellcome Inc. Androstenones
US6268377B1 (en) * 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
US6645974B2 (en) * 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
MXPA04010408A (es) 2002-04-24 2005-02-17 Boehringer Ingelheim Pharma Combinacion farmaceutica para el tratamiento de hiperplasia prostatica benigna o para la prevencion a largo plazo de la retencion urinaria aguda.
US20060019989A1 (en) * 2004-07-21 2006-01-26 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors and SERMs and methods of use thereof
WO2023101256A1 (ko) * 2021-12-03 2023-06-08 주식회사 팜어스바이오사이언스 5-알파-환원효소 억제제, 그의 약학적으로 허용 가능한 염 및 그 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions

Also Published As

Publication number Publication date
EP0285383A3 (en) 1990-09-12
EP0285383B1 (de) 1994-03-16
EP0285383A2 (de) 1988-10-05
CY1808A (en) 1995-09-08
CA1302276C (en) 1992-06-02
HK116594A (en) 1994-11-04
DE3888378T2 (de) 1994-09-29

Similar Documents

Publication Publication Date Title
DE3888378D1 (de) Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
DE68909219D1 (de) Behandlung von obesitas.
DE3675356D1 (de) Behandlung von kupferblaettern.
DE3584013D1 (de) Zubereitung zur behandlung von psoriasis.
FI874671A0 (fi) Anordning foer foerhindrande av laeckage i tryckledningar.
DE3670827D1 (de) Magnetische behandlung harten wassers.
DE69019488D1 (de) Behandlung von Geflügel.
DE3587741D1 (de) Behandlung von Hautkrankheiten.
DE68907423D1 (de) Behandlung der akne.
DE69018043T3 (de) Behandlung von Geflügel.
DE3670310D1 (de) Elektrochemische behandlung von ligninen.
DE3777861D1 (de) Behandlung von gasen.
DE3770184D1 (de) Behandlung von gasstroemen.
DE3888994D1 (de) Behandlung von androgener Alopecia mit 17-beta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen.
DE3674947D1 (de) Saatbehandlung.
ATE112172T1 (de) Targetformer von antitumor-methyltrithioagenzien.
DE3885913D1 (de) Aufbereitung von Alkoxysilanen.
DE3680881D1 (de) Behandlung von hologrammen.
DE68911776D1 (de) Konjugierte Oxybutenolide zur Behandlung von Ulcera.
DE68923219D1 (de) Behandlung von Abfällen.
DE68908344D1 (de) Oberflaechenbehandlung von metallen.
NO881255L (no) Behandling av fluider.
DE3765583D1 (de) Oberflaechenbehandlungsmittel und -verfahren.
DE3674321D1 (de) Behandlung geschmeidiger gewebe.
DE3777800D1 (de) Behandlung der wollstoffe.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition